Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410592 · ClinicalTrials.gov registry record · Phase 4
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT00410592 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 90 participants.
The verdict
NCT00410592, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study will be conducted in order to determine safety and efficacy esomeprazole, lansoprazole and pantoprazole control stomach acid by measuring the stomach acid in men and women of Hispanic origin who have GERD.
Interventions
- DRUG Esomeprazole 40mg
- DRUG Pantoprazole 40mg
- DRUG Lansoprazole 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410592
The ClinicalTrials.gov registry entry for NCT00410592 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Esomeprazole 40mg is the first listed.
NCT00410592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410592 about?
NCT00410592 is a clinical study titled "Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD". This study will be conducted in order to determine safety and efficacy esomeprazole, lansoprazole and pantoprazole control stomach acid by measuring the stomach acid in men and women of Hispanic origin who have GERD.
What is the current status of trial NCT00410592?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2006-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00410592?
The interventions under investigation include: Esomeprazole 40mg (DRUG), Pantoprazole 40mg (DRUG), Lansoprazole 30mg (DRUG).
Who is sponsoring clinical trial NCT00410592?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.